GlassScriptPhysician profile
Miranda L Reed
NPI 1659684231
$9,329.41
in general payments reported to CMS, 2019-2025
26 companies · $911 in 2025
The $911 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,666 · 2020: $318 · 2021: $1,980 · 2022: $1,604 · 2023: $1,238 · 2024: $612 · 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,033 · Travel and Lodging: $728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,032.94 |
| Travel and Lodging | $728.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $6,452.99 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Superion Indirect Decompression System |
| Nevro Corp. | $884.65 | 2019-2022 | |
| Spr Therapeutics, INC | $659.58 | 2022 | |
| Leo Pharma INC. | $349.09 | 2023-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $171.47 | 2022-2025 | Ilumya |
| Galderma Laboratories, L.P. | $134.19 | 2019 | |
| Mayne Pharma Commercial LLC | $71.81 | 2019-2025 | |
| Abbott Laboratories | $65.08 | 2021-2023 | Proclaim |
| Pacira Therapeutics, INC. | $52.07 | 2019-2020 | |
| Avanos Medical | $49.93 | 2021 | |
| Abbvie INC. | $49.76 | 2025 | |
| Medtronic, INC. | $40.43 | 2024-2025 | Intellis Adaptivestim, Synchromedii |
| Journey Medical Corporation | $39.75 | 2019 | |
| Biotronik Nro, INC. | $38.84 | 2025 | |
| Lilly USA, LLC | $37.90 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $36.99 | 2022-2024 | Tremfya |
| Vyne Pharmaceuticals INC. | $30.10 | 2020 | |
| Novartis Pharmaceuticals Corporation | $22.29 | 2020 | |
| Allergan, INC. | $21.28 | 2020 | |
| Mml US, INC. | $20.17 | 2025 | Reactiv8 |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.11 | 2025 | Jublia |
| Merz North America, INC. | $18.73 | 2019 | |
| Pfizer INC. | $17.48 | 2019 | |
| Amgen INC. | $16.19 | 2021 | |
| Hikma Pharmaceuticals USA | $14.38 | 2022 | |
| Horizon Therapeutics Plc | $14.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.